PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of apmJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Adv Prev Med. 2012; 2012: 731604.
Published online Oct 17, 2011. doi:  10.1155/2012/731604
PMCID: PMC3199075
Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges
Mary Kate Hart, 1 * George A. Saviolakis, 1 Susan L. Welkos, 2 and Robert V. House 1
1DynPort Vaccine Company LLC, Frederick, MD 21702, USA
2Bacteriology Division, USAMRIID, Frederick, MD 21701, USA
*Mary Kate Hart: mhart20/at/csc.com
Academic Editor: Kelly T. McKee
Received April 29, 2011; Revised July 20, 2011; Accepted July 21, 2011.
Abstract
The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational exposure to botulinum neurotoxins A1 and B1 and a second for Yersinia pestis, with the ultimate goal of licensure by the FDA under the Animal Rule. Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges are described in this chapter.
Articles from Advances in Preventive Medicine are provided here courtesy of
Hindawi Publishing Corporation